Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

cabel - I think, even without signs of efficacy, it certainly is "good news" to report on toxicity levels (previous PRs have stated that maximums have not been reached) and reports on how the body processes (circulates/excretes) Keventrin and the more these processes work similar to the pre-clinicals, the better. These are all positives in my book, worthy of discussion at ASCO and attendance.

On a related note, does anyone know the dosing frequency of the cohorts. I want to say I remember that the initial low dose was administered once a week...? How does this compare to the pre-clinics, seems like most of those were daily doses (with a break at some point). How or why would we expect efficacy if the patients are getting a once-a-week dose? Are cohorts 2,3 and 4 getting more FREQUENT dosing as well, or just higher doses?

Thanks,
Jeff